GALT Healthcare

Galectin Therapeutics Inc.

$3.35+0.60%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 337.8M USD
Enterprise value: 470.7M USD
Full-time employees: 9

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Galectin Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Galectin Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Galectin Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

—

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 53.1% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-8.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-4.7%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-41.0%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.39

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.71Sector median: 0.6250 · MAD: 0.3380

Current ratio0.10×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score -1.29Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Galectin Therapeutics

Is Galectin Therapeutics getting weaker?: Its latest SEC filing (Aug 14, 2026) got weaker in some ways: share count up 53.1%.
How is Galectin Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -8.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.2% vs peers 1.5% (weaker than 100% of peers).
Is Galectin Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Galectin Therapeutics?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Galectin Therapeutics?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.39 vs a peer median of 0.63 (stronger than 70% of peers).Beta 0.39 vs peers 0.63 (stronger than 70% of peers). Current ratio 0.10× vs a peer median of 2.59× (weaker than 100% of peers).Current ratio 0.10× vs peers 2.59× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 14, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 53.1% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Net income (12 months)	−26.3M USD	−27.8M USD	+6.1%
Cash	14.1M USD	13.3M USD	−6.0%
Shares outstanding	65.9M	100.8M	+53.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-73.0%	-182.2%	-145.6%	-268.9%	-157.9%	▲ 111 pts
Return on equity (ROE)	-3418.5%	—	—	—	—	—
Current ratio	4.63×	1.58×	1.77×	0.49×	2.42×	▲ 397%
Interest coverage	-61.72×	-37.13×	-13.64×	-7.66×	-2.74×	▲ 64%

GALT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Galectin Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Galectin Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Galectin Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Galectin Therapeutics

Is Galectin Therapeutics getting weaker?

Its latest SEC filing (Aug 14, 2026) got weaker in some ways: share count up 53.1%.

How is Galectin Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -8.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.2% vs peers 1.5% (weaker than 100% of peers).

Is Galectin Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Galectin Therapeutics?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Galectin Therapeutics?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.39 vs a peer median of 0.63 (stronger than 70% of peers).Beta 0.39 vs peers 0.63 (stronger than 70% of peers). Current ratio 0.10× vs a peer median of 2.59× (weaker than 100% of peers).Current ratio 0.10× vs peers 2.59× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−26.3M USD

−27.8M USD

+6.1%

Cash

14.1M USD

13.3M USD

−6.0%

Shares outstanding

65.9M

100.8M

+53.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-73.0%

-182.2%

-145.6%

-268.9%

-157.9%

▲ 111 pts

Return on equity (ROE)

-3418.5%

—

Current ratio

4.63×

1.58×

1.77×

0.49×

2.42×

▲ 397%

Interest coverage

-61.72×

-37.13×

-13.64×

-7.66×

-2.74×

▲ 64%